Baird Initiates Coverage on Varian Medical (VAR) with a Neutral
More News related to VAR
- Soleil Securities Upgrades Varian Medical Systems (VAR) to Buy; Raises FY10-11 Estimates & PT
- Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
- Varian Medical (VAR) Posts Q4 EPS of $0.78, Beats by 4c; Guides
- Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009
- Varian Medical Systems to Exhibit Technology Enhancements Designed to Improve Speed and Precision of Radiotherapy at ASTRO 2009
More News related to New Coverage
- XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
- Natixis Bleichroeder Downgrades Tenaris S.A. (TS) to Reduce
- Bank of America Downgrades Seneca Foods (SENEB) from Buy
- RBC Downgrades Intrepid Potash (IPI) to Sector Perform
Baird initiates coverage on Varian Medical (NYSE: VAR) with a Neutral. Price target $41.
To see more analyst ratings on VAR Click Here.
Varian Medical Systems, Inc. is engaged in designing, manufacturing, selling and servicing equipments and software products for treating cancer with radiotherapy, stereotactic radiosurgery and brachytherapy.
Related Categories
New CoverageStocks Mentioned
+1.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
